<DOC>
	<DOCNO>NCT01358708</DOCNO>
	<brief_summary>Irritable bowel syndrome complex condition high unmet medical need effective safe treatment option . Lacteol® lactobacillus product use adjunctive symptomatic treatment diarrhea . In study , Lacteol® 340 mg evaluate potential therapy treatment diarrhea-predominant irritable bowel syndrome ( IBS-D ) .</brief_summary>
	<brief_title>Treatment Diarrhea-predominant Irritable Bowel Syndrome ( IBS-D ) With LACTEOL® 340 mg</brief_title>
	<detailed_description>This study include follow phase : Screening Phase , Run-In Phase , Double-Blind Treatment Phase Open-Label Treatment Phase . Screening : Eligibility subject evaluate follow informed consent signature . Screening procedures/evaluations ( physical exam , concomitant medication , clinical laboratory test ) confirmation eligibility follow Rome III Diagnostic questionnaire perform . Run-In : Subjects enter 2-week Run-In Phase IBS Symptoms Stool Characteristics record . At end Run-In Phase , data collect last week review . Upon confirmation IBS-D severity status , subject may randomize . Double-Blind Treatment : Subjects take study medication ( either LACTEOL® 340 mg Placebo ) 28 day . During time , IBS Symptoms Stool Characteristics global assessment relief record , clinical laboratory test perform . HAD score assessed end double blind treatment . Open-Label Treatment : All study completers eligible second 28 day Open-Label Treatment event IBS-D symptom remain recur within month follow end Double-Blind Treatment . Subjects take study medication ( LACTEOL® 340 mg ) 28 day . During time , IBS Symptoms Stool Characteristics global assessment relief record , clinical laboratory test perform .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>IBSD diagnosis use Rome III questionnaire IBS Symptoms Severity Scale ( IBSSSS ) score range 100 400 Bristol Stool Form Scale score exceed two ( &gt; 2 ) less seven ( &lt; 7 ) Stable diet Mental legal ability sign inform consent Diagnosis Inflammatory Bowel Disease ( IBD ) Chronic use systemic steroid Diagnosis autoimmune Diseases Disorders Invasive abdominal surgery Use antibiotic prior screen Allergy active substance ingredient LACTEOL® 340 mg Congenital galactosemia , glucose , fructose and/or galactose malabsorption syndrome , lactase deficiency lactose intolerance Diagnosis exocrine pancreatic insufficiency Use experimental drug within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>